SFM
CYTK icon

Signet Financial Management’s Cytokinetics CYTK Stock Holding History

Signet Financial Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,483
Closed -$68K – 480
2021
Q4 		$68K Buy
+1,483
New +$57.2K 0.01% 402

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Signet Financial Management's CYTK Position: Q1 2022 in Review

Signet Financial Management sold out of Cytokinetics (CYTK) in Q1 2022, closing a stake of 1,483 shares — an estimated $68K sold.

Signet Financial Management first reported a position in CYTK in Q4 2021 and held it in 1 quarter. The position peaked at $68K in Q4 2021. 240 funds tracked by Wall St. Rank hold CYTK as of Q1 2022.

  • Signet Financial Management reported no remaining Cytokinetics position as of Q1 2022 after selling out during the quarter.
  • Signet Financial Management sold 1,483 Cytokinetics shares in Q1 2022, an estimated $68K.
  • Signet Financial Management first reported a position in Cytokinetics in Q4 2021 and held it in 1 quarter.
  • Signet Financial Management's Cytokinetics position peaked at $68K in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2022.

Based on Signet Financial Management's 13F filing for Q1 2022, filed 13 May 2022.